News
Pfizer signs license agreement to allow wider global access to its experimental Covid-19 antiviral drug
The agreement with the Drug Patent Organization, a public health organization backed by the United Nations, will allow conventional drugmakers to make the drug widely available in 95 countries, the company said. low- and middle-income, comprising 53% of the world’s population.
The pill, called PF-07321332 or Paxlovid, is taken in combination with an older antiviral medicine called ritonavir.
Earlier this month Pfizer announced top results from its trial says that an interim analysis – performed before the trial is scheduled to end – showed an 89% reduction in the risk of hospitalization or death from Covid-19 in those given the drug within the first three days of the onset of symptoms.
“Pfizer will not accept royalties on sales in low-income countries and will additionally waive royalties on sales in all countries covered by the agreement while COVID-19 is still covered by the World Health Organization.” World Classified as a Public Health Emergency of International Concern,” Pfizer said in the statement.
.
